Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Human Genome Sciences Inc., a GSK Company
With
GlaxoSmithKline
The purpose of this continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with Systemic Lupus Erythematosus (SLE), that completed study LBSL02 and benefitted from treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Have completed the LBSL02 trial and achieved a satisfactory response.
You may not be if
1. Required more than 2 courses of corticosteroids for treatment of severe SLE flares in the last 5 months of LBSL02.
2. Had an SLE flare during the last 30 days of LBSL02 and through the 1st dose in LBSL99.
3. Used any of the following prohibited medications during their participation in LBSL02:
